FDA Approves G1 Therapeutics’ Cosela to Prevent Chemo Damage in Lung CancerApprovals, Bone Marrow, Chemotherapy, Chemotherapy-induced myelosuppression, Clinical Data, Clinical Trials, Extensive-Stage Small Cell Lung Cancer, FDA, FDA/Regulatory, Immune System, Myelosuppression, R&D, TherapeuticsThe U.S. Food and Drug Administration approved G1 Therapeutics’ Cosela (trilaciclib) for injection to decrease the damage to the immune system and bone marrow from chemotherapy. Read more February 15, 2021/by Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2021/02/FDA-Approves-G1-Therapeutics-Cosela-to-Prevent-Chemo-Damage-in-Lung-Cancer-BioSpace-2-15-21.jpeg 350 625 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2021-02-15 14:50:442021-02-15 14:55:47FDA Approves G1 Therapeutics’ Cosela to Prevent Chemo Damage in Lung Cancer